Schleiermacher G, Delattre O
Inserm U.509, Pathologie moléculaire des cancers, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.
Bull Cancer. 2001 Jun;88(6):561-70.
The extension of a cancer is a major prognostic factor which determines the therapeutic strategy. The occurrence of metastatic relapses in patients with initially localized tumours, despite a good local control, gives evidence for the possibility of spreading of occult tumour cells. The recent improvements of immunohistochemistry and molecular biology methods enable to detect tumour cells in various sites such as lymph nodes, bone marrow and blood with a considerably increased sensitivity as compared to conventional approaches. The markers used to detect tumour cells by PCR or RT-PCR can be either "tissue-specific" or "tumour specific". The drawback of the first group of markers is linked to the observation that tissue-specificity is frequently a relative concept leading to a high rate of false positives. Tumour-specific markers include gene fusions observed in various sarcomas, point mutations and presence of viral genomes in tumour cells. They are available and can be easily monitored in only a limited set of cancers. This review focuses on the molecular biology approaches which are used to detect occult tumour cells and on their clinical applications. The large number of studies which have been published in that field show that such a detection can be performed in a variety of target sites. However, results of studies performed on larger series of patients together with a better standardization of technics are necessary before they can be used for individual staging of patients.
癌症的分期是决定治疗策略的主要预后因素。对于初始局限期肿瘤患者,尽管局部控制良好,但仍会发生转移复发,这证明了隐匿肿瘤细胞存在播散的可能性。与传统方法相比,免疫组织化学和分子生物学方法的最新进展能够以显著提高的灵敏度在诸如淋巴结、骨髓和血液等各种部位检测肿瘤细胞。通过PCR或RT-PCR检测肿瘤细胞所使用的标志物可以是“组织特异性”的或“肿瘤特异性”的。第一组标志物的缺点与以下观察结果有关:组织特异性往往是一个相对的概念,导致假阳性率很高。肿瘤特异性标志物包括在各种肉瘤中观察到的基因融合、点突变以及肿瘤细胞中病毒基因组的存在。它们仅在有限的一组癌症中可用且易于监测。本综述重点关注用于检测隐匿肿瘤细胞的分子生物学方法及其临床应用。该领域已发表的大量研究表明,这种检测可以在多种靶部位进行。然而,在将其用于患者的个体分期之前,需要对更大系列的患者进行研究,并使技术更好地标准化。